Parker Institute adds Dana-Farber, Gladstone Institutes to cancer research collaboration
Click Here to Manage Email Alerts
Parker Institute for Cancer Immunotherapy added Dana-Farber Cancer Institute and Gladstone Institutes to its immuno-oncology research partnership network.
Both institutions will establish new cancer immunology research centers funded by grants from Parker Institute for Cancer Immunotherapy (PICI) as part of their membership.
The goal of the network and its funding is to encourage “bold, high-risk scientific research” with the aim of bringing together academic research and biotech companies for the development of new cancer therapies, according to a PICI-issued press release.
“We are excited to welcome Dana-Farber and Gladstone Institutes to the PICI network, where they join the world’s top cancer research centers,” Sean Parker, PICI’s founder and chairman, said in the release. “The continued growth of the PICI network represents unprecedented collaboration in the fight against cancer and will enable us to accelerate breakthrough treatments to cancer patients.”
Alex Marson, MD, PhD — professor of medicine at University of California, San Francisco — will serve as director of the new Gladstone-UCSF Institute of Genomic Immunology, which will focus on cancer research using genomics and CRISPR technology to manipulate the human immune system. Other institute members include Gladstone assistant investigator Karin Pelka, PhD, and Ansuman Satpathy, MD, PhD, affiliate investigator at Gladstone and assistant professor in the department of pathology at Stanford School of Medicine.
Laurie H. Glimcher, MD — president and CEO of Dana-Farber Cancer Institute — will serve as director of the new Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute. The entity will focus on the role of the tumor microenvironment and seek to translate basic scientific insights into new and clinically impactful cancer immunotherapies.
F. Stephen Hodi Jr., MD, Elizabeth Mittendorf, MD, PhD, and Kai Wucherpfennig, MD, PhD, will serve as co-directors of the center.
“Dana-Farber investigators are innovators in immuno-oncology,” Glimcher said in a Dana-Farber-issued press release. “As an institutional member of the PICI network, we will have even more opportunity to work jointly with fellow leaders in the field, bringing together a powerful combination of expertise and resources that will have an even greater impact on patients.”
Reference s :
- Dana-Farber Cancer Institute. Dana-Farber joins Parker Institute for Cancer Immunotherapy to accelerate cures for the world’s gravest cancers (press release). Available at: www.dana-farber.org/newsroom/news-releases/2022/dana-farber-joins-parker-institute-for-cancer-immunotherapy-to-accelerate-cures-for-the-world-s-gravest-cancers/. Published: Sept. 28, 2022. Accessed Oct. 3, 2022.
- Gladstone Institutes. Gladstone Institutes joins the Parker Institute for Cancer Immunotherapy network (press release). Available at: https://gladstone.org/news/gladstone-institutes-joins-parker-institute-cancer-immunotherapy-network. Published Sept. 28, 2022. Accessed Oct. 3, 2022.
- Parker Institute for Cancer Immunotherapy. PICI welcomes Dana-Farber and Gladstone Institutes to its network of leading experts advancing cures for cancer (press release). Available at: www.parkerici.org/the-latest/pici-welcomes-dana-farber-and-gladstone-institutes. Published: Sept. 28, 2022. Accessed Oct. 3, 2022.
Click Here to Manage Email Alerts